GSK takes NICE risk with Votrient for RCC
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has recommended GlaxoSmithKline's targeted oral anticancer Votrient (pazopanib) as a new first-line treatment for NHS patients with advanced renal cell carcinoma (RCC). The recommendation hinged on a two-part patient access scheme, which could involve a rebate for the NHS depending on forthcoming trial results.